Sweetening of Glutamine Metabolism in Cancer Cells by Rho GTPases Through Convergence of Multiple Oncogenic Signaling Pathways by Dorai, Thambi et al.
Touro Scholar 
NYMC Faculty Publications Faculty 
8-2016 
Sweetening of Glutamine Metabolism in Cancer Cells by Rho 
GTPases Through Convergence of Multiple Oncogenic Signaling 
Pathways 
Thambi Dorai 
New York Medical College 
John T. Pinto 
New York Medical College 
Arthur J. L. Cooper 
New York Medical College 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs 
 Part of the Biochemistry Commons, and the Enzymes and Coenzymes Commons 
Recommended Citation 
Dorai, T., Pinto, J. T., & Cooper, A. J. L. (2016). Sweetening of glutamine metabolism in cancer cells by Rho 
GTPases through convergence of multiple oncogenic signaling pathways. Translational Cancer Research, 
5, S356. doi:10.21037/tcr.2016.07.43 
This Response or Comment is brought to you for free and open access by the Faculty at Touro Scholar. It has been 
accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more 
information, please contact touro.scholar@touro.edu. 
© Translational Cancer Research. All rights reserved. Transl Cancer Res 2016;5(S2):S349-S356 tcr.amegroups.com
More than 60 years ago, Otto Warburg showed that cancer 
cells exhibit enhanced glycolysis accompanied by greatly 
elevated levels of lactate secretion, even in the presence of 
normal levels of oxygen (1). Warburg suggested that cancer 
cells arise from normal cells in a two-phase process: phase 1 
is “injury” to the respiratory machinery (i.e., mitochondria), 
followed in phase 2 by enhanced “fermentation” (i.e., 
production of lactate from glucose) in the protoplasm (i.e., 
cytosol) (1). Conversion of glucose to lactate as a source 
of ATP is very inefficient compared to that obtained by 
complete oxidation of glucose to CO2 via tight coupling of 
glycolysis to the mitochondrial TCA cycle. Nevertheless, 
Warburg suggested that given ready access to adequate 
circulating glucose “fermentation” can provide quiescent 
cancer cells with the necessary energy requirements (1). For 
many years the Warburg effect was treated mainly as just 
another interesting biochemical phenomenon. However, 
within the last decade the “Warburg effect” has become 
the subject of intense investigation. We now know that the 
mitochondria in many cancer cells are not grossly defective 
as originally envisaged by Warburg, but are metabolically 
reprogrammed (2). In this case, the carbon of certain 
metabolites can enter the TCA cycle (anaplerosis) as both an 
energy source and as a source of intracellular components 
(e.g., for lipids, nucleic acids, proteins) necessary for rapidly 
dividing cells. An especially important metabolite in this 
regard is glutamine (3). Rapidly dividing cancer cells that 
require substantial amounts of glutamine are said to exhibit 
“glutamine addiction”. Glutamine is readily converted to 
the TCA cycle intermediate α-ketoglutarate (α-KG) while 
at the same time providing nitrogen for DNA, polyamine 
and non-essential amino acid synthesis. Glutamine is 
converted to α-KG in a two-step process. Glutamine is 
hydrolyzed to glutamate by glutaminase, which in turn 
is converted to α-KG by the glutamate dehydrogenase 
reaction or by transamination with a suitable α-keto acid 
substrate (4).
The importance of the Warburg effect and glutamine 
metabolism in cancer cells was elegantly demonstrated by 
DeBerardinis et al. (5). These authors used 13C-glucose 
coupled to 13C-NMR to show that glioblastoma cells in 
culture copiously convert glucose to lactate (and, to a lesser 
extent alanine) in the presence of oxygen. Moreover, using 
13C-glutamine the authors showed that glutamine is also 
an important energy source in these cells (glutaminolysis). 
In these studies, a substantial portion of glutamine carbon 
(60%) was shown to be directed toward lactate production. 
DeBerardinis et al. state “A by-product of this flux is robust 
NADPH production by malic enzyme. The glutaminolytic flux 
was at least as high as the G6PDH flux, and appeared to be 
higher than that needed for fatty acid synthesis. This could mean 
that NADPH generated during glutaminolysis also supplies other 
anabolic processes such as nucleotide biosynthesis.” Interestingly, 
glutamine nitrogen was lost to the medium not only 
as alanine but also as ammonia. Apparently, although 
glutamine is a source of nitrogen for many compounds in 
the glioblastoma cells the utilization of glutamine carbon 
through the TCA cycle provides nitrogen in excess of that 
needed for these biosynthetic reactions and is excreted in 
the form of alanine and ammonia (5).
A crucial enzyme in the glutaminolysis pathway is 
glutaminase (6). In mammals, GLS and GLS2 genes encode 
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two glutaminase isozymes. GLS encodes a kidney-type 
glutaminase (GLS) and a splice variant [glutaminase C 
(GAC)]. GLS2 encodes a liver-type glutaminase (GLS2) 
and a splice variant [glutaminase B (GAB)] (7). Thus, it 
is not surprising that several cellular oncogenes and their 
signaling pathways regulate glutaminase activity in cancer 
cells. For example, many cancer cells that express high 
levels of c-Myc exhibit elevated glutaminase activity (8), 
which is associated with de-repression of glutaminase by the 
microRNA mir23a/b (9). Thus, a molecular link between an 
oncogenic signal and elevated glutaminase activity has been 
established. However, this link is not unique to cancer cells 
because several non-cancerous diseases, such as pulmonary 
hypertension are also associated with increased glutamine 
metabolism in the affected cells (10). Because of the unique 
role of glutaminase in disease processes, intense efforts 
have been directed toward the development of selective and 
potent glutaminase inhibitors.
One such glutaminase inhibitor was identified by Wang et al. 
as a brominated phenanthridinone derivative (compound 968), 
which was discovered during a chemical screen for inhibitors 
of a class of oncogenic signaling proteins, namely Rho 
GTPases (11). In this study, the compound was found to: (I) 
block oncogenic transformation induced by a well-known 
guanine nucleotide exchange factor in fibroblasts; and (II) 
block the growth of human breast cancer and B lymphoma 
cells, without affecting normal cells (11). A biotinylated 
derivative of compound 968, when used in a streptavidin 
pull-down assay revealed that its target protein is the 
mitochondrial glutaminase (GLS) (11). Additional studies 
by Wang et al. showed specific down-regulation of GLS by 
siRNA is associated with suppression of colony formation of 
cells that constitutively express the oncogenic Rho GTPase 
family member diffuse B-cell lymphoma (dbl) (11). Further 
studies revealed that glutaminase inhibition strongly 
suppresses breast cancer cell proliferation and confirmed a 
molecular link between elevated glutaminase activity and 
oncogenic transformation of cells that express Rho GTPase 
family members (11). The increase in glutaminase activity 
in these cells was also found to depend on the expression of 
NF-κB (11). Interestingly, these studies also revealed that 
the inhibitory effect of the compound 968 could be partially 
reversed by the supplementation with α-KG, a metabolite 
in the TCA cycle downstream of GLS activity. Thus, these 
studies established the importance of glutaminase activity 
in cancer cells along with its importance in the anaplerotic 
provision of the TCA cycle intermediate α-KG in cancer 
cell growth.
A follow-up of the study by Wang et al. (11) by the same 
group (and the subject of the current commentary) provides 
a mechanistic link between the action of Rho GTPases and 
the elevation of glutaminase activity (7). In these studies 
another potent inhibitor of GLS/GAC was used, namely 
bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 
(BPTES). In this study, Lukey et al. concluded that: (I) the 
oncogenic transcription factor c-Jun is responsible for the 
elevation of glutaminase activity by Rho GTPase family 
members; (II) c-Jun is an important regulator of GLS 
expression in human breast cancer; and (III) overexpression 
of this cellular proto-oncogene is sufficient to sensitize 
breast cancer cells to glutaminase-targeted therapy. Thus, 
these studies are further confirmation of the importance 
of glutaminase activity as an important step in providing 
anaplerotic α-KG, critical for cancer cell growth.
These findings are significant for the following reasons: 
first, they highlight the contribution of the protein product 
of the oncogene c-JUN, (which is overexpressed and/or 
stabilized in many cancers, including breast cancer) in the 
metabolic rewiring of cancers and provide a molecular 
explanation for the increased dependency on glutamine 
metabolism. Second, they offer an explanation for the 
coordinated metabolic reprogramming and signaling that 
is required for concomitant increases in cell proliferation 
and biomass. Finally, elevated expression of GLS in triple 
negative breast cancer (TNBC), as opposed to estrogen 
receptor positive (ER+) breast cancer, is now known to be 
associated with an increase in the protein levels of both 
proto-oncogenes c-JUN and c-MYC, which transcriptionally 
upregulate GLS mRNA (12,13). Thus, targeting GLS in 
TNBC is the basis for several currently ongoing clinical 
trials. 
Despite advances in our understanding of the overall 
importance of glutaminase activity in cancer metabolism, 
there are still some unresolved issues. First, whereas GLS 
is upregulated by several oncogenes such as c-MYC and 
c-JUN, GLS2 is upregulated by the tumor suppressor 
protein p53 (14,15). Although wild type p53 contributes to 
the upregulation of glutaminase it has the added property 
of promoting antioxidant activity through the increased 
production of glutathione, which in turn is associated 
with a significant reduction in tumor development. Thus, 
Myc- or Jun-induced glutaminolysis supports cancer 
cell proliferation, whereas p53-induced glutaminolysis is 
associated with tumor suppression. Hence, there is a need 
for the design of: (I) compounds that inhibit GLS but not 
GLS2; and (II) compounds that activate GLS2. In this 
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respect, strategies that are aimed to rescue mutant p53 
(which is expressed in a significant fraction of solid tumors) 
and restore its normal function (16) gain more significance, 
namely their role in reprogramming of glutamine 
metabolism for cancer therapeutic purposes.
Second, the recent report by Lukey et al. emphasizes 
the role of c-Jun signaling downstream of the Rho 
GTPase activation in the upregulation of glutaminase 
activity (7). Earlier work by the same group highlights the 
importance of NF-κB signaling downstream of the same 
family of Rho GTPases (11). It is interesting to note that 
mutated p53 stimulates the mevalonate pathway, which 
provides the geranylgeranyl pyrophosphate moieties 
covalently linked to Rho family members for insertion 
into membranes, contributing to their activation (17). 
By contrast, as described above, wild type p53 enhances 
GLS2 expression (14,15). The use of glutamine either in 
normal cell function or in proliferation mirrors the ability 
of p53 to induce or suppress reactive oxygen species (ROS) 
production. More importantly, GLS is upregulated by the 
cellular oncogene c-MYC, which negatively controls the 
glutaminase-suppressing microRNA, miR23a/b (9). The 
cellular oncogene c-SRC, which was the first tyrosine kinase 
oncogene to be discovered, also regulates glutaminase 
metabolism indirectly through c-MYC. In a recent study, Jain 
et al. showed that SRC blockade reduces glucose metabolism 
and the Warburg effect in breast cancer cells through the 
inhibition of extracellular signal regulated kinase (ERK)1/2-
MNK1-eIF4E-mediated cap-dependent translation 
of c-MYC and the glucose transporter GLUT1 (18). 
In addition, Src is known to activate the Rho GTPase Rac1 
through the participation of the adaptor oncogene CRKII 
and p120 catenin (19,20). These observations suggest 
that Rho GTPases activate the Jun N-terminal kinase 
(JNK), which, in turn, phosphorylates c-Jun, thus strongly 
activating its properties as a transcription factor. Moreover, 
evidence suggests the participation of the proliferation/
angiogenesis and metastasis suppressor protein SSeCKS 
(pronounced Essex) [Src suppressed C-kinase substrate; 
a member of the myristoylated alanine-rich C-kinase 
substrate (MARCKS) family] in the control of signaling 
pathways in oncogenesis (21). We propose a hypothesis that 
integrates the activities of several oncogenes and the tumor 
suppressor gene p53 (Figure 1). However, the major tenet 
of this hypothesis, namely the involvement of SSeCKS or 
MARCKS family of proteins needs to be verified. MARCKS 
and related SSeCKS proteins serve as a reversible source of 
phosphoinositides (particularly PIP2), sequestering them 
in the plasma membrane and preventing their conversion 
into PIP3. This sequestration inactivates phosphoinositide-
dependent kinase (PDK) thus attenuating PI 3-kinase and 
Akt (22). SSeCKS, which is also known as AKAP12 or 
gravin, functions as a tumor and metastasis suppressor (23). 
Recent studies have shown that the functions of SSeCKS/
AKAP12 likely involve its ability to negatively influence 
specific oncogenic signaling pathways through the 
scaffolding of key mitogenic mediators such as PKC, PKA, 
cyclins and calmodulin by an electrostatic switch mechanism 
acting at the membrane (24). Conversely, loss of SSeCKS 
activity, either by down-regulated gene expression or by 
phosphorylation leads to hyperactivated PKC-isoenzymes, 
which in turn leads to increased invasiveness in prostate 
cancer cells (25).
Studies by Gelman and coworkers (23) clearly establish 
the suppressive role of SSeCKS in Src-induced oncogenesis 
by regulating the Rho GTPase family members, namely 
RhoA- and Cdc42-dependent pathways. Since SSeCKS/
AKAP12 controls cellular events that cause scaffolding of 
key signaling molecules such as cyclin D1, calmodulin, 
PKA, and PKC, this effect would help re-establish the 
actin-based cytoskeletal architecture (23). Additionally, 
c-JNK phosphorylation of the MARCKS family member 
MARCKSL1 determines actin stability, cytoskeletal 
structure and cell movement, which are important for 
cancer cell invasiveness, as shown in a prostate cancer 
model system (26). Working along similar lines, Cohen 
and coworkers have shown that forced re-expression of 
the down-regulated SSeCKS reversed the v-Jun induced 
transformation of 10T1/2 murine fibroblasts (27). These 
observations suggest that: (I) there is a nexus of regulatory 
signaling pathways connecting PKC and Rho GTPases 
to the SSeCKS protein, leading to its down-regulation 
in cancer; and (II) a down-regulation of SSeCKS is a 
requirement of v-Jun-induced oncogenic transformation. 
The oncogenic v-Jun protein differs from c-Jun by two 
amino-acid substitutions in the C-terminal DNA binding 
domain and an N-terminal 27 amino acid deletion. Hence, 
it is very likely that down-regulation of SSeCKS is also an 
oncogenic pre-requisite for c-Jun-overexpressing cancer 
cells, including human cancers. Cohen and colleagues (27) 
have also shown that SSeCKS functions as a tumor 
suppressor, counteracting the oncogenic effect of Jun as well 
as Src. Thus, it will be very interesting to determine how 
Rho GTPase family members that activate JNK negatively 
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Figure 1 Proposed convergence of signaling pathways from several oncogenes and tumor suppressor gene p53 to reprogram glutamine 
metabolism. An integrated view of the participation of Src, Myc, NF-κB, c-Jun and p53 proteins is presented. Glutaminase (kidney type, 
GLS) is upregulated by multiple oncogenic transcription factors, such as c-Myc, c-Src and c-Jun. In addition, wild type p53 transcriptionally 
upregulates the liver type glutaminase (GLS2) stimulating potent anti-tumorigenic and anti-oxidant properties of the cell. Intriguingly, 
mutant p53 activates the oncogenic Rho GTPases by providing the necessary membrane anchor (the geranylgeranyl moiety) derived from 
the mevalonate pathway. Several PKC enzymes associate with Rho GTPases in their activation of Jun kinase activity [Jun N-terminal kinase 
(JNK)]. In the proposed unifying hypothesis, these proteins act in concert to down-regulate or inactivate (by phosphorylation) the scaffolding 
protein SSeCKS of the myristoylated alanine-rich C-kinase substrate (MARCKS) family of proteins and this down-regulation is linked to 
an up-regulation of JNK activity, thus enhancing the phosphorylation of the oncogenic transcription factor c-Jun. In the publication serving 
as the basis for the present commentary, Lukey et al. showed that c-Jun is the transcription factor that is activated by phosphorylation, 
which subsequently binds to the kidney type glutaminase (GLS) promoter and upregulates the expression of GLS, thereby reprogramming 
glutamine metabolism in cancer cells. Thus, the expression/activity of MARCKS/SSeCKS and the activity of the transcription factor c-Jun 
are proposed to be inversely related. Incidentally, the Rho family of proteins and the MARCKS proteins are implicated in the release of large 
extracellular vesicles, which may explain the dual role of GTPase regulation in the reprogramming of glutamine metabolism as well as in 
the alteration of the cytoskeletal architecture necessary for vesicle release. Importantly, this may give a molecular explanation for the genesis 
of cancer cell dormancy (see the text for details). The signaling pathway where the hypothesized connection to the MARCKS/SSeCKS 
proteins is made is denoted by a question mark (?). It is possible that glutamine positively regulates RhoA and JNK directly as shown by 
an intense blue arrow in the figure which would then set up a vicious cycle wherein glutamine facilitates its own hydrolysis, a phenomenon 
which could be co-opted by the cancer cells for highly demanding proliferative purposes. It is also possible that glutamine directly activates 
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influence the expression of MARCKS or related SSeCKS 
proteins. This may provide a molecular explanation for the 
mechanism by which Rho GTPases activate JNK, which 
in turn activates c-JUN specific transcription, providing 
a molecular link to the studies by Lukey et al. (7). Several 
pieces of indirect evidence suggest the participation of 
proteins such as MARCKS in the activation of JNK. For 
example, one study showed that the MARCKS protein 
regulates the expression of pro-inflammatory cytokines in 
murine macrophages through the activation of JNK and 
NF-κB (28). It is worth noting in this context that SSeCKS, 
MARCKS and the extracellular matrix protein SPARC are 
down-regulated in v-Jun transformed cells (29). Thus, it 
is very likely that in human cancers over-expressing c-Jun, 
the same genes such as SSeCKS and MARCKS may be 
targeted for negative regulation. These studies suggest that 
a molecular relationship may exist between Rho GTPases 
and elevated JNK signaling (leading to c-JUN activation), 
and that the MARCKS/SSeCKS family of proteins may 
provide the link connecting the two (Figure 1). Therefore, it 
would be very interesting to determine the expression levels 
of MARCKS/SSeCKS and whether a re-expression or over-
expression of MARCKS or SSeCKS negatively influences 
glutaminase expression as seen in the experimental system 
employed by Lukey et al. (7).
Third, Lukey et al. have shown that a cell-permeable 
α-KG precursor partially rescues the growth of dbl-
expressing mouse embryonic fibroblasts (MEFs) (7). 
This raises the immediate concern that cancer cells that 
reprogram metabolic pathways and elevate intracellular 
α-KG will negate the therapeutic potential of glutaminase-
targeted therapies currently under investigation. Several 
bypass mechanisms for obtaining anaplerotic carbon are 
potentially available to the cancer cell and it would be 
important to investigate their participation before clinically 
testing any anti-glutaminase therapies.
Fourth, it is interesting to note that an important 
connection between RhoA-mediated elevation of glutaminase 
and the generation of large extracellular vesicles has been 
observed in cancer cells (30). Notably, introduction of specific 
glutaminase inhibitors (compound 968 or BPTES) strongly 
inhibits the shedding of these large extracellular vesicles in a 
variety of cancers such as glioblastoma, metastatic mammary 
gland adenocarcinoma, pancreatic ductal carcinoma, and 
pancreatic adenocarcinoma (31).
Thus, it appears that reprogramming of glutamine 
metabolism and elevated glutaminase activity meet the 
metabolic demands for increased biomass and lipid 
synthesis required to replace the plasma membranes lost 
from these cancer cells as extraverted vesicles. In this 
respect, it is intriguing that, in a recent study, exosomes 
from bone marrow mesenchymal cells were shown to 
contain a microRNA (miR23b) directed against MARCKS 
mRNA that promotes dormancy in metastatic breast 
cancer cells (32). Apparently, breast cancer cells fuse with 
vesicles containing miR23b, inducing suppression of 
the gene MARCKS. This observation has at least three 
important implications. First, the miR23b when taken 
up by the target cancer cells may also down-regulate the 
expression of GLS, thus preventing the reprogramming of 
glutamine metabolism, which is crucially needed for cell 
proliferation and increased metabolic demands. Second, 
suppressing glutamine metabolism (in the absence of the 
c-Myc signal) may promote cancer cell dormancy, such as 
in micrometastases. An increase in GLS may then function 
as a “wake up” signal for dormant cancer cells to emerge 
as a proliferating cancer cell. Third, the observation that 
miR23b also targets MARCKS protein along with GLS 
strongly supports the hypothesis (Figure 1) that MARCKS/
SSeCKS integrates in the Rho GTPases/GLS regulatory 
mechanism.
Fifth, glutamine is the most abundant free amino acid 
in the body and is well known to play a regulatory role in 
several cell specific processes such as apoptosis and cell 
proliferation (33). Glutamine also has a role in activating 
metabolism, signal transducing and redox processes, and 
in stimulating gluconeogenesis, lipogenesis, extracellular 
matrix production, respiratory burst/cell defenses and heat 
shock response/chaperone functions (33). Thus, the function 
of glutamine transcends its classical roles as a simple building 
block for proteins, a metabolic fuel and a nitrogen source for 
various biomolecules. Importantly, glutamine plays a role in 
potentiating the effects of growth factors that facilitate gene 
expression, cell proliferation and repair (34). In this regard, 
Rhoads et al. have shown that glutamine activates both 
extracellular ERK and JNK in intestinal cell proliferation. 
These proteins are involved in signal transduction pathways 
stimulated by growth factors, resulting in an increase in 
AP-1-dependent gene transcription and c-Jun mRNA levels, 
positively regulating the expression of genes involved in cell 
division (35). Moreover, glutamine activates the mTORC1 
cell proliferation pathway both directly and indirectly 
through the import of leucine through a bidirectional 
transport mechanism (36). Therefore, while the studies 
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by Lukey et al. (7) have focused on GLS activity, it is also 
possible that glutamine per se may have a direct effect 
in activating JNK under certain cellular circumstances. 
In consideration of this direct effect, a vicious circle 
of events may occur wherein glutamine activates JNK, 
JNK phosphorylates c-Jun, and phosphorylated-c-Jun 
translocates to the nucleus and activates transcription of 
GLS. The resultant GLS translocates to the mitochondria 
where it catalyzes the hydrolysis of glutamine to glutamate 
and ammonium. Interestingly, a recent report shows that 
glutamine and its dipeptide analog alanyl-glutamine can 
increase RhoA expression in intestinal epithelial cells (37). 
Therefore, future investigations must take into account the 
participation of glutamine in activating its own metabolism, 
a phenomenon that could be exploited by cancer cells 
through Rho GTPases. These observations not only 
highlight the importance of the studies by Lukey et al. (7) 
in contributing to our understanding of individual signaling 
processes involved in the glutamine addiction of cancer 
cells, but also support the hypothesis that several signaling 
pathways converge synergistically in this process (Figure 1).
Finally, several very recent reports indicate that the 
“glutamine addiction” observed in several cancer cell lines 
in culture is not exactly reproduced in vivo, suggesting that 
the tumor microenvironment may play an important role in 
the reprogramming of glutamine metabolism and hence the 
metabolic phenotype (38,39). Thus, within the core of the 
tumor, metabolic heterogeneity may exist with respect to 
glutamine dependency, which may or may not be sensitive 
to glutaminase-targeted therapies (38-40). This raises 
question of how the c-Jun activated pathways are regulated 
by gradients in nutrient concentrations within the highly 
perfused and poorly perfused regions of the same tumor.
In conclusion, additional studies are needed to 
evaluate and interpret the therapeutic potential of 
glutaminase inhibitors, especially within cancers that have 
reprogrammed glutamine metabolism. Lastly, a better 
understanding of the Warburg effect is beginning to emerge 
with regard to the metabolic influences of glutaminase. 
The paper by Lukey et al. is timely and significant since it 
focuses on the role of altered oncogenic signaling pathways 
in the rewiring of cancer cell metabolism and should lay the 
foundation for personalized and targeted therapy of cancer 
patients, based on their metabolic phenotype.
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